



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



BI-749327

Item No. 39672

CAS Registry No.: 2361241-23-6
Formal Name: [4-(6-amino-3-pyridazinyl)-1-piperidinyl][4-[4-(trifluoromethyl)phenoxy]phenyl]-methanone
MF: C₂₃H₂₁F₃N₄O₂
FW: 442.4
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BI-749327 is supplied as a solid. A stock solution may be made by dissolving the BI-749327 in the solvent of choice, which should be purged with an inert gas. BI-749327 is sparingly soluble (1-10 mg/ml) in DMSO and slightly soluble (0.1-1 mg/ml) in acetonitrile.

Description

BI-749327 is an inhibitor of transient receptor potential canonical 6 (TRPC6; IC₅₀ = 13 nM for the mouse channel).¹ It is selective for TRPC6 over TRPC3 and TRPC7 (IC₅₀s = 1,100 and 550 nM, respectively, for the mouse channels). BI-749327 (100, 250, and 500 nM) inhibits TRPC6-mediated reporter gene expression in HEK293T cells expressing mouse TRPC6. *In vivo*, BI-749327 (30 mg/kg) decreases myocardial interstitial fibrosis in a mouse model of hypertrophic cardiomyopathy induced by transaortic constriction. It reduces unilateral ureteral obstruction-induced renal fibrosis in mice. BI-749327 (30 mg/kg) also increases survival, decreases myocardial fibrosis, and improves grip strength in a mouse model of Duchenne muscular dystrophy (DMD).²

References

1. Lin, B.L., Matera, D., Doerner, J.F., *et al.* *In vivo* selective inhibition of TRPC6 by antagonist BI 749327 ameliorates fibrosis and dysfunction in cardiac and renal disease. *Proc. Natl. Acad. Sci. USA* **116**(20), 10156-10161 (2019).
2. Lin, B.L., Shin, J.Y., Jeffreys, W.P., *et al.* Pharmacological TRPC6 inhibition improves survival and muscle function in mice with Duchenne muscular dystrophy. *JCI Insight* **7**(19), e158906 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/17/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM